SMO and acute myeloid leukemia: In a similar context, previous RNAi screening of acute myeloid leukemia (AML) cell lines under 5-AzaC treatment identified genes of the SHH pathway as targetable molecular vulnerabilities, reporting for the first time synergism between SMO inhibitor and 5-AzaC when combined concurrently in vitro for AML [60].